[Anhedonia as target symptom in personalized therapy of patients with mood disorders and alcohol use disorder comorbidity].

The relatively low response of anhedonia symptom in the case of MD/AUD comorbidity compared with the «pure» MD, makes perspective using antidepressants with prodophaminergic mechanism of action in this cohort of patients. Furthermore, in MD/AUD comorbidity, contrary to «pure» MD, a relative increase in melatonin concentration in blood serum was detected, therefore it could be a limitation to prescribing antidepressants directly or indirectly modulating melatoninergic system.